Market Overview:
The global IV and oral iron drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of anemia, rising geriatric population, and growing demand for better treatment options. The oral iron drugs segment is expected to grow at a higher CAGR than the IV iron drugs segment during the forecast period. This can be attributed to factors such as lower cost and easy availability of oral iron drugs as compared to IV iron drugs. The nephrology application segment is expected to dominate the global IV and oral iron drug market in terms of revenue during the forecast period from 2018to 2030 owingto high prevalenceof anemia among patients with chronic kidney disease (CKD)and other renal disorders.
Product Definition:
IV and oral iron drugs are used to treat iron deficiency anemia. Iron is necessary for the production of hemoglobin, which carries oxygen in the blood. Oral iron drugs are taken by mouth, while IV iron drugs are given through a vein.
Oral Iron Drug:
Oral Iron Drugs are the drugs that help to increase the amount of hemoglobin in blood cells by increasing absorption ability of iron from gastrointestinal tract. The drug is available in different forms such as tablets, powders, liquids and injections. It’s consumption increases when there is a decrease or absence of hemoglobin in blood due to anemia or sickle cell disease. Anemia can be caused due to chronic diseases like cancer, infections and heavy losses etc.
IVIron Drugs:
Iron is an essential mineral for the body, but if a person does not have enough of it in their bodies, it can cause problems. Iron deficiency leads to anemia which causes weakness and fatigue. It also makes the cells slow down and cannot carry oxygen to tissues and organs that need it most.
IVIron drugs are medicines given by vein (intravenous) or by mouth (oral).
Application Insights:
The nephrology segment dominated the global market in terms of revenue share in 2017. The growth can be attributed to the increasing prevalence of chronic kidney diseases (CKD) and rising awareness about preventive measures against CKD. According to a study published by National Kidney Foundation (NKF), around 1 out of 3 people aged 65 years or above have some form of CKD, which accounts for over 60 million Americans. Moreover, as per data published by CDC, around 15% adults in U.S., have an estimated glomerular filtration rate (GFR) less than 90 mL/min/1.73 m2 which is considered as normal stage for CKD and 30% GFR between 90-150 mL/min/1.73 m2 are at high risk for developing end-stage renal disease (ESRD).
Regional Analysis:
North America dominated the global market in terms of revenue share in 2017. The presence of a large number of pharmaceutical companies, advanced healthcare infrastructure and high patient awareness levels regarding available treatment options are some factors attributing to its largest share.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing prevalence rates for chronic kidney diseases coupled with growing medical expenditure levels in emerging economies such as India and China. Moreover, rising disposable income levels will also contribute towards this growth during the forecast period. In addition, improving healthcare facilities due to government initiatives is anticipated to further boost regional market development over the coming years (8).
Growth Factors:
- Increasing prevalence of anemia: The increasing prevalence of anemia is one of the key growth drivers for the IV and oral iron drugs market. According to a study by the World Health Organization (WHO), approximately 1.62 billion people were affected by anemia in 2013, and this number is expected to increase to 1.85 billion by 2025. This growing population base is likely to drive demand for IV and oral iron drugs in the coming years.
- Rising awareness about anemia: There is a growing awareness among people about anemia and its various causes, symptoms, and treatment options. This is leading more people to seek medical help for managing their condition, which in turn is driving demand for IV and oral iron drugs products globally.
Scope Of The Report
Report Attributes
Report Details
Report Title
IV and Oral Iron Drugs Market Research Report
By Type
Oral Iron Drug, IVIron Drugs
By Application
Nephrology, OBGYN, Surgeries, Gastroenterology, Oncology, Heart failure (HF)
By Companies
Daiichi Sankyo Company, Vifor Pharma, Akebia Therapeutics, Allergan, AMAG Pharmaceuticals, AOP Orphan Pharmaceuticals, Pharmacosmos, Sanofi, Shield Therapeutics, AZAD Pharma, Cirondrugs, MEDICE, Pfizer, Salveo Lifecare, Sunny Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
194
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global IV and Oral Iron Drugs Market Report Segments:
The global IV and Oral Iron Drugs market is segmented on the basis of:
Types
Oral Iron Drug, IVIron Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Nephrology, OBGYN, Surgeries, Gastroenterology, Oncology, Heart failure (HF)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Daiichi Sankyo Company
- Vifor Pharma
- Akebia Therapeutics
- Allergan
- AMAG Pharmaceuticals
- AOP Orphan Pharmaceuticals
- Pharmacosmos
- Sanofi
- Shield Therapeutics
- AZAD Pharma
- Cirondrugs
- MEDICE
- Pfizer
- Salveo Lifecare
- Sunny Pharmaceutical
Highlights of The IV and Oral Iron Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral Iron Drug
- IVIron Drugs
- By Application:
- Nephrology
- OBGYN
- Surgeries
- Gastroenterology
- Oncology
- Heart failure (HF)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the IV and Oral Iron Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
IV iron drugs are medications that are given by injection into a vein. Oral iron drugs are medications that you take by mouth.
Some of the major companies in the iv and oral iron drugs market are Daiichi Sankyo Company, Vifor Pharma, Akebia Therapeutics, Allergan, AMAG Pharmaceuticals, AOP Orphan Pharmaceuticals, Pharmacosmos, Sanofi, Shield Therapeutics, AZAD Pharma, Cirondrugs, MEDICE, Pfizer, Salveo Lifecare, Sunny Pharmaceutical.
The iv and oral iron drugs market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 IV and Oral Iron Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 IV and Oral Iron Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 IV and Oral Iron Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the IV and Oral Iron Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global IV and Oral Iron Drugs Market Size & Forecast, 2018-2028
4.5.1 IV and Oral Iron Drugs Market Size and Y-o-Y Growth
4.5.2 IV and Oral Iron Drugs Market Absolute $ Opportunity
Chapter 5 Global IV and Oral Iron Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 IV and Oral Iron Drugs Market Size Forecast by Type
5.2.1 Oral Iron Drug
5.2.2 IVIron Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global IV and Oral Iron Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 IV and Oral Iron Drugs Market Size Forecast by Applications
6.2.1 Nephrology
6.2.2 OBGYN
6.2.3 Surgeries
6.2.4 Gastroenterology
6.2.5 Oncology
6.2.6 Heart failure (HF)
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global IV and Oral Iron Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 IV and Oral Iron Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America IV and Oral Iron Drugs Analysis and Forecast
9.1 Introduction
9.2 North America IV and Oral Iron Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America IV and Oral Iron Drugs Market Size Forecast by Type
9.6.1 Oral Iron Drug
9.6.2 IVIron Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America IV and Oral Iron Drugs Market Size Forecast by Applications
9.10.1 Nephrology
9.10.2 OBGYN
9.10.3 Surgeries
9.10.4 Gastroenterology
9.10.5 Oncology
9.10.6 Heart failure (HF)
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe IV and Oral Iron Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe IV and Oral Iron Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe IV and Oral Iron Drugs Market Size Forecast by Type
10.6.1 Oral Iron Drug
10.6.2 IVIron Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe IV and Oral Iron Drugs Market Size Forecast by Applications
10.10.1 Nephrology
10.10.2 OBGYN
10.10.3 Surgeries
10.10.4 Gastroenterology
10.10.5 Oncology
10.10.6 Heart failure (HF)
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific IV and Oral Iron Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific IV and Oral Iron Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific IV and Oral Iron Drugs Market Size Forecast by Type
11.6.1 Oral Iron Drug
11.6.2 IVIron Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific IV and Oral Iron Drugs Market Size Forecast by Applications
11.10.1 Nephrology
11.10.2 OBGYN
11.10.3 Surgeries
11.10.4 Gastroenterology
11.10.5 Oncology
11.10.6 Heart failure (HF)
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America IV and Oral Iron Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America IV and Oral Iron Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America IV and Oral Iron Drugs Market Size Forecast by Type
12.6.1 Oral Iron Drug
12.6.2 IVIron Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America IV and Oral Iron Drugs Market Size Forecast by Applications
12.10.1 Nephrology
12.10.2 OBGYN
12.10.3 Surgeries
12.10.4 Gastroenterology
12.10.5 Oncology
12.10.6 Heart failure (HF)
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) IV and Oral Iron Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) IV and Oral Iron Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) IV and Oral Iron Drugs Market Size Forecast by Type
13.6.1 Oral Iron Drug
13.6.2 IVIron Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) IV and Oral Iron Drugs Market Size Forecast by Applications
13.10.1 Nephrology
13.10.2 OBGYN
13.10.3 Surgeries
13.10.4 Gastroenterology
13.10.5 Oncology
13.10.6 Heart failure (HF)
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 IV and Oral Iron Drugs Market: Competitive Dashboard
14.2 Global IV and Oral Iron Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Daiichi Sankyo Company
14.3.2 Vifor Pharma
14.3.3 Akebia Therapeutics
14.3.4 Allergan
14.3.5 AMAG Pharmaceuticals
14.3.6 AOP Orphan Pharmaceuticals
14.3.7 Pharmacosmos
14.3.8 Sanofi
14.3.9 Shield Therapeutics
14.3.10 AZAD Pharma
14.3.11 Cirondrugs
14.3.12 MEDICE
14.3.13 Pfizer
14.3.14 Salveo Lifecare
14.3.15 Sunny Pharmaceutical
